Carolyn Sue, MBBS, PhD, FRACP, is the executive director of the Kolling Institute and professor and director of neurogenetics at Royal North Shore Hospital, University of Sydney. Dr. Sue is a clinician-scientist, recognized for her expertise in mitochondrial function as it relates to mitochondrial and other neurodegenerative diseases. Her research team combines the use of genomics, molecular neuroscience, and adult stem cell models to identify pathogenic mechanisms and develop targeted therapies for Parkinson’s disease and other related neurodegenerative disorders. Her contributions to the field have been in gene discovery, biomarker development, application of next generation sequencing protocols and bioinformatic pipeline development for improved diagnostic pathways, and the identification novel targets for the treatment of Parkinson’s disease.
COLLABORATING PI
Carolyn Sue, PhD
The University of Sydney's Kolling Institute at the Royal North Shore Hospital
Carolyn Sue, MBBS, PhD, FRACP, is the executive director of the Kolling Institute and professor and director of neurogenetics at Royal North Shore Hospital, University of Sydney. Dr. Sue is a clinician-scientist, recognized for her expertise in mitochondrial function as it relates to mitochondrial and other neurodegenerative diseases. Her research team combines the use of genomics, molecular neuroscience, and adult stem cell models to identify pathogenic mechanisms and develop targeted therapies for Parkinson’s disease and other related neurodegenerative disorders. Her contributions to the field have been in gene discovery, biomarker development, application of next generation sequencing protocols and bioinformatic pipeline development for improved diagnostic pathways, and the identification novel targets for the treatment of Parkinson’s disease.
